Cargando…
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
BACKGROUND: The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations. METHODS: Clinical data and KRAS mutational status were analysed in patients treated with nivolumab within the Italian Expanded Access Program. Object...
Autores principales: | Passiglia, Francesco, Cappuzzo, Federico, Alabiso, Oscar, Bettini, Anna Cecilia, Bidoli, Paolo, Chiari, Rita, Defferrari, Carlotta, Delmonte, Angelo, Finocchiaro, Giovanna, Francini, Guido, Gelsomino, Francesco, Giannarelli, Diana, Giordano, Monica, Illiano, Alfonso, Livi, Lorenzo, Martelli, Olga, Natoli, Clara, Puppo, Gianfranco, Ricevuto, Enrico, Roca, Elisa, Turci, Daniele, Galetta, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325128/ https://www.ncbi.nlm.nih.gov/pubmed/30377342 http://dx.doi.org/10.1038/s41416-018-0234-3 |
Ejemplares similares
-
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
por: Landi, Lorenza, et al.
Publicado: (2019) -
Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016) -
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
por: Verzoni, Elena, et al.
Publicado: (2019) -
Monitoring blood biomarkers to predict nivolumab effectiveness in
NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019) -
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)